Company intelligence / Profile preview

Shenzhen YHLO Biotech

Shenzhen, Guangdong, Chinaen.szyhlo.com ↗

Ownership: Private
Employees: ~1750
Development stage: Commercial

Overview

YHLO has over a decade of commercial success with more than 300 diagnostic products on the market. Its solutions are widely used in hospitals and clinics across China and exported to over 115 countries. The company’s technologies have been referenced in more than 980 scientific publications as of August 2024. No clinical trial results apply as it does not develop therapeutics.

Therapeutic areas: PulmonologyInfectious DiseasesImmunologyGastroenterologyWomen's Health
Modalities: Chemiluminescence immunoassay (CLIA)Immunofluorescence assayImmunoblotting assayFluorescent immunochromatography assayColloidal gold immunochromatography assay
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Shenzhen YHLO Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen YHLO Biotech.

Explore the full profile